|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Leukemia progression was associated with increased Bcl-2 expression and cell viability, reduced p27(Kip1) expression, and decreased cell-cycle progression.
|
21593192 |
2011 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BCL-2 expression in childhood leukemia versus spontaneous apoptosis, drug induced apoptosis, and in vitro drug resistance.
|
10500808 |
1999 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity.
|
10652595 |
2000 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.
|
23333149 |
2013 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BCL2 is also overexpressed in CLL, the most common human leukemia.
|
28653191 |
2019 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells.
|
9242431 |
1997 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis.
|
9989821 |
1999 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A common insertional polymorphism in promoter of MCL1, a member of BCL2 family gene with the dual regulatory functions, has been shown to be functional in leukemia, but its association with cancer predisposition and prognosis has not been well established.
|
21887682 |
2012 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A naked RNA heptamer targeting the human Bcl-2 mRNA induces apoptosis of HL60 leukemia cells.
|
23092557 |
2013 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abbreviations: APC/C: Anaphase-Promoting Complex/Cyclosome; BAD: BCL2-Associated agonist of cell Death; BAK1: BCL2 Antagonist Kinase1; BAX: BCL2-Associated X; BCL2: B-cell Chronic Lymphocytic Leukaemia (CLL)/Lymphoma 2; BH: BCL2 Homology Domain; BID: BH3-Interacting domain Death agonist; BIM: BCL2-Interacting Mediator of cell death; BUB: Budding Uninhibited by Benzimidazoles; CDC: Cell Division Cycle; CDH1: Cadherin-1; CDK1: Cyclin-Dependent Kinase 1; CEP55: Centrosomal Protein (55 KDa): CIN: Chromosomal Instability; CTA: Cancer Testis Antigen; EGR1: Early Growth Response protein 1; ERK: Extracellular Signal-Regulated Kinase; ESCRT: Endosomal Sorting Complexes Required for Transport; GIN: Genomic Instability; MAD2: Mitotic Arrest Deficient 2; MCL1: Myeloid Cell Leukemia sequence 1; MPS1: Monopolar Spindle 1 Kinase; MYT1: MYelin Transcription factor 1; PLK1: Polo Like Kinase 1; PUMA: p53-Upregulated Mediator of Apoptosis; SAC: Spindle Assembly Checkpoint; TAA: Tumor-Associated Antigen.
|
30601084 |
2019 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-xl and Bcl-w, has demonstrated efficacy in several forms of leukemia, lymphoma as well as solid tumors.
|
19684859 |
2009 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After arsenic treatment of the leukemia cell lines HL-60 and K562 the up-regulation of par-4 may contribute to the induction of apoptosis rather than down-regulation of bcl-2.
|
16966277 |
2006 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antiapoptotic BCL-2 is required for maintenance of a model leukemia.
|
15380515 |
2004 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antisense oligodeoxynucleotides specific for sequences in mRNAs from the B-cell lymphoma/leukemia-2 (BCL2) gene were used to inhibit the growth in culture of a human leukemia cell line, 697.
|
2208117 |
1990 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As far as we know, this is the first report on the effects of bcl-2 ASO on childhood leukemia/lymphoma cell samples.
|
18575824 |
2008 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
BLI and PB were subsequently used to evaluate efficacy of the Bcl-2 inhibitor venetoclax.<b>Results:</b> BLI considerably accelerated and enhanced detection of leukemia burden compared with PB and identified sites of residual disease during treatment in a quantitative manner, highlighting limitations in current PB-based scoring criteria.
|
28119366 |
2017 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CD200 was more frequent in secondary compared to de novo leukemia (p = 0.0006), in CD34 positive cases (p = 0.00001), in Bcl2 overexpressing cases (p = 0.01), in those wild-type Flt3 (p = 0.004) and with favorable or unfavorable compared to intermediate karyotype (p = 0.0003).
|
26338961 |
2015 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell culture, tissue chemistry and flow cytometry were used to determine whether antisense bcl-2 oligodeoxynucleotides enhanced the sensitivity of leukemia cells to arsenic trioxide.
|
14642526 |
2003 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chronic lymphocytic leukemia (CLL) is the most common human leukemia and is characterized by predominantly nondividing malignant B cells overexpressing the antiapoptotic B cell lymphoma 2 (Bcl2) protein. miR-15a and miR-16-1 are deleted or down-regulated in the majority of CLLs.
|
16166262 |
2005 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compound 7a notably inhibited the expression and activity of PIM kinases, as evidenced by reduced B‑cell lymphoma‑2 (Bcl‑2)‑associated death promoter phosphorylation at Ser112.
|
31789392 |
2020 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of BCL-2 family proteins by leukemia fusion genes.
|
28717011 |
2017 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Following confirmation of the natural history of this leukemia in the transgenic mice, we demonstrated that the transformed murine lymphocytes express relevant therapeutic targets (Bcl-2, Mcl-1, AKT, PDK1, and DNMT1), wild-type p53 status, and in vitro sensitivity to therapeutic agents relevant to the treatment of human CLL.
|
16670263 |
2006 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given that many human chronic lymphocytic leukemias overexpress TRAF1 and Bcl-2, our findings suggest that cooperation between Bcl-2 and TRAF pathways contributes to the development of this type of leukemia.
|
15545599 |
2004 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Greater potential for therapeutic intervention rests with targeting molecular aberrations and altered gene expression in leukemia cells, for example, over expression of the anti-apoptotic proteins of the Bcl-2 family.
|
15869733 |
2005 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death.
|
12931228 |
2003 |